ERBB2 and breast cancer: Recently, a subgroup analysis of the KAMILLA study, which assessed the efficacy of ado-trastuzumab emtansine in metastatic HER2 + BC, revealed that 42.9% of the patients with baseline measurable brain metastases (n = 126) had a reduction in the size of the CNS lesions by at least 30%61.